Of note, experimental inhibition of UBE2C suppressed the malignant phenotypes, surpassing cisplatin resistance in ovarian and non-small cell lung cancers [69,74], in parallel with overcoming sorafenib resistance in HCC [73]. Here, UBE2C is linked to non-small cell lung carcinoma.